I'm very interested in their solutions for saliva and swab tests to be revealed later this year. This could create some significant I.P if it's anything like their blood-based solutions. The new Elion product looks fantastic.
Atomo will be the Apple for POCT, with ease of use, simplicity and accuracy at the forefront. Coupled with a digital telehealth enabled app this will be the gold standard for decentralised diagnostics.
This will be one of those investments you to look back on in 3-5 years and wish you bought and held. As John Kelly mentioned, the volatility and share price will sort itself out once annuity-style revenues become predictable.
